.After increasing $170 thousand back in February, metabolic disease-focused BioAge Labs has submitted to debut on the public market.The Eli Lilly-partnered biotech hopes to list on the Nasdaq under the sign “BIOA,” according to records submitted with the Stocks and also Swap Commission. The company has actually certainly not openly shared an anticipated financial amount for the offering.The clinical-stage provider touts lead applicant azelaprag, an orally delivered small particle slated to enter phase 2 screening in combo along with semaglutide– sold by Novo Nordisk under brand Wegovy for fat loss– in the very first half of next year. Semaglutide is additionally sold as Ozempic and Rybelsus by Novo for diabetes.
Apelin receptor agonist azelaprag is designed to combine well along with GLP-1 medicines, improving fat burning while maintaining muscular tissue mass. The investigational medicine was actually discovered to be well-tolerated one of 265 people throughout eight stage 1 tests, depending on to BioAge.Earlier, BioAge gathered the support of Lilly to operate a trial blending azelaprag with the Large Pharma’s GLP-1/ GIP receptor agonist tirzepatide, which is industried for diabetes mellitus as Mounjaro and Zepbound for fat burning. The partners are actually currently administering a phase 2 test of azelaprag as well as tirzepatide, along with topline results anticipated in the third fourth of 2025.The biotech is actually additionally planning a blood insulin sensitivity proof-of-concept test evaluating azelaprag as a monotherapy in the first fifty percent of next year to sustain possible indicator growth.
In addition, the business considers to ask the FDA for approval in the 2nd fifty percent of 2025 to release human screening for an NLRP3 prevention targeting metabolic illness and also neuroinflammation.BioAge’s expected move to everyone market complies with a mild uptick in intended biotech IPOs coming from Bicara Therapeutics and also Zenas Biopharma. Zooming out, the latest IPO landscape is actually a “blended picture,” along with high quality providers still debuting on everyone markets, just in reduced varieties, depending on to PitchBook.